Drug intelligence / Profile preview

L-756423

Development stage: Phase 2
Lead developer: Merck
Modality: Small Molecules

Overview

L-756423 is a potent, selective, and competitive small molecule inhibitor of HIV protease (HIV-1 PR), developed by Merck & Co. It is chemically similar to indinavir but features a longer half-life in animal models. The compound was investigated as an antiviral agent for the treatment of HIV infections and reached phase II clinical trials before development was discontinued. Its mechanism involves direct inhibition of the HIV protease enzyme, thereby blocking viral replication[3][5][9].

Other names: UNII-862SGU1BRLUNII862SGU1BRLUNII 862SGU1BRL

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on L-756423.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L-756423.

Explore the full profile